BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//London Global Cancer Week - ECPv6.18.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:London Global Cancer Week
X-ORIGINAL-URL:https://www.lgcw.org.uk
X-WR-CALDESC:Events for London Global Cancer Week
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Etc/GMT
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Etc/GMT:20241113T120000
DTEND;TZID=Etc/GMT:20241113T130000
DTSTAMP:20241027T123607Z
CREATED:20241021T201403Z
LAST-MODIFIED:20241027T123607Z
UID:30018-1731499200-1731502800@www.lgcw.org.uk
SUMMARY:“Opportunities in Latin America for improving precision medicine in oncology”
DESCRIPTION:Register \nContext and Rationale \nCancer treatment has seen remarkable progress in recent years\, largely due to the advancements in precision medicine. This innovative approach enables personalized treatments that are tailored to the genetic and molecular characteristics of each patient’s tumor\, revolutionizing the way cancer is treated. With the help of precision diagnostics and genetic testing\, oncologists can now identify specific mutations that drive cancer growth\, paving the way for targeted therapies that are not only more effective but also less toxic than traditional treatments. These breakthroughs have led to significantly improved patient outcomes\, particularly in Europe and the United States\, where health systems have invested heavily in integrating these technologies into standard oncology care. \nIn regions like Europe and the U.S.\, organizations such as ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) have been at the forefront of research and clinical application of precision oncology. Experts in these organizations have helped shape the development and implementation of cutting-edge therapies\, as well as frameworks for precision diagnostics that have set a global benchmark. Their work has provided the foundation for clinical guidelines that support the integration of genetic profiling and biomarker-driven treatments in cancer care. These developments have not only enhanced treatment efficacy but also reduced the economic and physical burden of ineffective therapies. \nHowever\, while these advancements have become more commonplace in Europe and the U.S.\, Latin America faces significant challenges in replicating this progress. There are substantial gaps in infrastructure\, technology\, and funding across the region\, which hinder the adoption of precision medicine. Many countries lack the capacity for widespread genetic testing and molecular diagnostics\, and access to targeted therapies is often limited to a few specialized centers\, creating disparities in care. Additionally\, regulatory frameworks and reimbursement models are not yet fully equipped to support these innovations\, making it difficult for patients to benefit from the full spectrum of precision oncology. \nThis meeting aims to bring together the leading Cancer Institutes of Latin America\, along with key stakeholders and global experts\, to assess the current state of precision medicine in the region. The goal is to diagnose the situational challenges and explore the opportunities for improving cancer care through precision oncology. By drawing on the expertise of professionals involved in ASCO and ESMO\, the meeting will also serve as a platform to share international best practices\, promote collaboration\, and create actionable strategies for overcoming the region’s barriers to innovation. \nMeeting Objectives \n1. Assess the current state of precision medicine and diagnostics in the region: \nReview progress in using molecular diagnostics\, genetic testing\, and the implementation of targeted therapies across different cancer types in Latin America. Identify barriers to accessing these technologies. \n2. Share best practices in genetic testing and targeted therapies: \nFacilitate the exchange of successful experiences in using genetic testing to identify key mutations and selecting appropriate targeted therapies for each patient. \n3. Foster collaboration between cancer institutions: \nExplore cooperation among Cancer Institutes and other organizations to create networks that improve diagnostic capabilities\, share genetic data\, and enhance access to precision therapies. \n4. Develop regional strategies to improve access to precision medicine: \nDiscuss public policies\, funding\, and regulatory frameworks that will help increase the availability of genetic testing and access to targeted therapies \n5. Proposed Agenda Topics \n1. Overview of precision diagnostics and genetic testing in Latin America: \nThe current state of access to advanced molecular diagnostics\, genetic sequencing\, and laboratory capacities across the region. \n2. Advances in targeted therapies (target therapies): \nLatest innovations in the use of targeted therapies and how genetic tests help identify key biomarkers to personalize cancer treatment. \n3. Challenges and barriers to implementing genetic testing and access to precision therapies: \nIdentification of financial\, technological\, and regulatory obstacles that limit the use of genetic testing in clinical practice and access to targeted treatments. \n4. Collaboration and regional networks to enhance access to precision medicine: \nExploration of collaborative models between countries to improve early diagnosis\, data sharing\, and equitable access to targeted therapies. \n5. Public policy to promote precision medicine in oncology: \nProposals for policies that encourage investment in advanced diagnostic technologies and facilitate access to innovative treatments through subsidies\, insurance coverage\, and price regulation. \nExpected Outcomes \n• A current analysis of the state of precision medicine\, genetic testing\, and access to targeted therapies in Latin America. \n• Identification of the main barriers countries face in implementing precision diagnostics and using targeted therapies. \n• Proposals for inter-institutional collaboration to optimize the use of molecular diagnostic technologies and improve accessibility to personalized treatments. \n• Strategic recommendations to improve public policies that promote precision medicine in the region.
URL:https://www.lgcw.org.uk/event/opportunities-in-latin-america-for-improving-precision-medicine-in-oncology/
LOCATION:Virtual
ATTACH;FMTTYPE=image/png:https://www.lgcw.org.uk/wp-content/uploads/2024/10/selac-logo.png
END:VEVENT
END:VCALENDAR